Potential clinical exploitation of the radiation-induced DNA damage response

Clin Oncol (R Coll Radiol). 2014 May;26(5):241-2. doi: 10.1016/j.clon.2014.02.005. Epub 2014 Mar 3.

Authors

R P Symonds¹, G D Jones²

Affiliations

¹ Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK.
² Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK. Electronic address: gdj2@le.ac.uk.

PMID: 24602565
DOI: 10.1016/j.clon.2014.02.005

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Antineoplastic Agents / pharmacology
Ataxia Telangiectasia / drug therapy
Ataxia Telangiectasia / genetics
Ataxia Telangiectasia Mutated Proteins / antagonists & inhibitors
Checkpoint Kinase 1
Checkpoint Kinase 2 / antagonists & inhibitors
Chemoradiotherapy
DNA / radiation effects*
DNA Damage / drug effects*
Drugs, Investigational / pharmacology
Genes, erbB-1 / drug effects
Genes, erbB-1 / radiation effects
Humans
Protein Kinases / drug effects
Radiation Injuries / prevention & control*
Radiobiology / trends
Vascular Endothelial Growth Factor A / drug effects
Vascular Endothelial Growth Factor A / radiation effects

Substances

Antineoplastic Agents
Drugs, Investigational
Vascular Endothelial Growth Factor A
DNA
Protein Kinases
Checkpoint Kinase 2
ATM protein, human
ATR protein, human
Ataxia Telangiectasia Mutated Proteins
CHEK2 protein, human
Checkpoint Kinase 1